RiDYMO® Designs Cyclic Peptide for "Undruggable" β-Catenin Target Within Two Months
BEIJING, Jan. 9, 2025 /PRNewswire/ -- In a recent achievement, DP Technology's hit discovery platform RiDYMO® has successfully designed a cyclic peptide targeting β-catenin, a historically "undruggable" protein, in just two months. This innovative...